Akebia Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
AKBA$0.53+32.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheet
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| (dollars in thousands, except per share amounts) | March 31,2025 | December 31,2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $113,374 | $51,870 |
| Inventories | 19,732 | 16,243 |
| Accounts receivable, net | 61,538 | 34,368 |
| Prepaid expenses and other current assets | 9,138 | 11,350 |
| Total current assets | 203,782 | 113,831 |
| Property and equipment, net | 1,904 | 2,200 |
| Operating right-of-use assets | 7,114 | 8,218 |
| Goodwill | 59,044 | 59,044 |
| Other long-term assets | 38,341 | 37,377 |
| Total assets | $310,185 | $220,670 |
| Liabilities and stockholders' deficit | ||
| Current liabilities: | ||
| Accounts payable | $12,658 | $15,180 |
| Accrued expenses and other current liabilities | 71,337 | 63,460 |
| Current portion of deferred revenue | 1,241 | — |
| Working Capital Fund liability, current portion | 5,991 | 2,274 |
| Total current liabilities | 91,227 | 80,914 |
| Long-term operating lease liabilities | 2,123 | 3,547 |
| Long-term debt, net | 46,511 | 38,693 |
| Liability related to settlement royalties, net of current portion | 47,440 | 46,697 |
| Liability related to sale of future royalties, net of current portion | 51,549 | 52,066 |
| Working Capital Fund liability, net of current portion | 34,420 | 38,013 |
| Warrant liability | 7,220 | 5,176 |
| Other long-term liabilities | 5,114 | 4,749 |
| Total liabilities | 285,604 | 269,855 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity (deficit): | ||
| Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at March 31, 2025 and December 31, 2024 | — | — |
| Common stock $0.00001 par value; 350,000,000 shares authorized at March 31, 2025 and December 31, 2024; 261,644,590 and 224,848,992 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 2 | 2 |
| Additional paid-in capital | 1,696,821 | 1,629,167 |
| Accumulated other comprehensive income | 6 | 6 |
| Accumulated deficit | (1,672,248) | (1,678,360) |
| Total stockholders' equity (deficit) | 24,581 | (49,185) |
| Total liabilities and stockholders' equity (deficit) | $310,185 | $220,670 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.